Endoscopic atlas of digestive disorders in COVID-19

1. Baklaushev V. P., Kulemzin S. V., Gorchakov A. A., et al. COVID-19. Etiology, pathogenesis, diagnosis and treatment. Clinical practice. 2020;11(1):7– 20. (in Russ.) doi:10.1017816/clinprakt263.

2. Interim Guidelines: Prevention, Diagnosis and Treatment of Novel Coronavirus Infection (COVID-19), in Version 15 of 02.22.2022. (in Russ.)

3. Turchina M. S., Mishina A. S., Veremeichik A. L., Reznikov R. G. Clinical features of gastrointestinal tract damage in pations with new coronaviral infection COVID-19. Challenges in modern medicine. 2020;44 (1): 5–15 (in Russ.)

4. D’Amico G., Garcia- Tsao G., Pagliaro L. et al. Natural history and prognostic survival rates in cirrhosis of the liver: a systematic review of 118 studies. J. Hepatol. 2006 Jan;44(1):217–31. doi: 10.1016/j.jhep.2005.10.013.

5. Hoffmann M., Kleine- Weber H., Schroeder S. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271– 280.e8. doi: 10.1016/j.cell.2020.02.052.

6. Sarsenbaevа A. S., Lazebnik L. B. Diarrhea when COVID-19 in adults. Experimental and Clinical Gastroenterology. 2020;(6):42–54. (In Russ.) doi: 10.31146/1682–8658-ecg-178–6–42–54.

7. Cheung J. Y., Wang J., Zhang X. Q., et al. Methylene blue counteracts cyanide cardiotoxicity: cellular mechanisms. J Appl Physiol (1985). 2018 May 1;124(5):1164–1176. doi: 10.1152/japplphysiol.00967.2017.

8. Ardatskaya M. D., Bel'mer S.V., Dobritsa V. P., et al. [Colon dysbacteriosis (dysbiosis): modern state of the problem, comprehensive diagnosis and treatment correction]. Eksp Klin Gastroenterol. 2015;(5):13–50. Russian. PMID: 26387170.

9. Ye Q., Wang B., Zhang T., Xu J., Shang S. The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19. Am. J. Physiol. Gastrointest. Liver. Physiol. 2020 Aug 1; 319(2): G245-G252. doi: 10.1152/ajpgj.00148.2020.

10. Mao R., Qiu Y., He J. S., et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 Jul;5(7):667–678. doi: 10.1016/S2468–1253(20)30126–6.

11. Yandrapu H., Marcinkiewicz M., Poplawski C., et al. Role of saliva in esophageal defense: implications in patients with nonerosive refl ux disease. Am J Med Sci. 2015 May;349(5):385–91. doi: 10.1097/MAJ.0000000000000443.

12. Pakhomova I. G. Patient with GERD after a new coronavirus infection. Rational pharmacotherapy in clinical case. RMJ. 2021;6:18–22 (in Russ.)

13. Denson J. L., Gillet A. S., Zu Y., et al; Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group. Metabolic Syndrome and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19. JAMA Netw Open. 2021 Dec 1;4(12): e2140568. doi: 10.1001/jamanetworkopen.2021.40568..

14. Alekseeva O. P., Pikulev D. V. Gastroesophageal Refl ux Disease and Coronary Heart Disease: Is There a “Mutual Burden” Syndrome? Russi an Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(4):66–73. (In Russ.) doi: 10.22416/1382–4376–2019–29–4–66–73.

15. Mohammed S. B., Gadad A., Nayak B. S., BeharryV. Prognosis of the Midlife- Elderly from ECG Testing to Gastroesophageal Refl ux Disease and Coronary Artery Disease. J Fam Med Dis Prev. 2016; 2:029. doi: 10.23937/2469–5793/1510029.

16. Pakhomova I. G., Zinovieva E. N. Gastro esophageal refl ux disease in a polymorbid patient: features of therapy. RMJ. 2017;10:760–764 (in Russ.)

17. Pakhomova I. G., Horoshinina L. P. NSAIDInduced Esophagopathy: Just GERD or Another Nosological Unit? Farmateka. 2016;15:39–43. (in Russ.)

18. Lazebnik L. B., Belova G. V. Moscow systematizing Classifi cation of Multifocal lesions of the digestive tract mucosa with nonsteroidal antiinfl ammatory (NSAIDs) and antithrombotic (ATP) drugs (MCMP), Recommendations for the prevention and treatment of esophagogastroenterocolopathies induced by non steroidal anti-inflammatory drugs. Approved by the XII National Congress of Therapists and the 18th Congress of the Scientific Society of Gastroenterologists of Russia (Moscow, November 23, 2017)

19. Pakhomova I. G. Patient with GERD after a new coronavirus infection. Rational pharmacotherapy in clinical case. RMJ. 2021;6:18–22 (in Russ.)

20. Suresh Kumar V. C., Mukherjee S., Harne P. S., et al. Novelty in the gut: a systematic review and meta-analysis of the gastrointestinal manifestations of COVID-19. BMJ Open Gastroenterol. 2020 May;7(1): e000417. doi: 10.1136/bmjgast-2020–000417.

21. Blevins C. H., Iyer P. G., Vela M. F., Katzka D. A. The Esophageal Epithelial Barrier in Health and Disease. Clin Gastroenterol Hepatol. 2018;- 16(5):608–617. doi: 10.1016/j.cgh.2017.06.035.

22. Yandrapu H., Marcinkiewicz M., Poplawski C., et al. Role of saliva in esophageal defense: implications in patients with nonerosive refl ux disease. Am J Med Sci. 2015 May;349(5):385–91. doi: 10.1097/MAJ.0000000000000443.

23. Ivashkin V. T., Trukhmanov A. S., Gonik M. I. The use of rebamipide in the treatment of gastroesophageal reflux disease. Terapevticheskiy ar khiv. 2020;92(4):98–104. (in Russ.) doi: 10.26442/00403660.2020.04.000568.

24. World Organization for Digestive Endoscopy (OMED). [Minimum Standard Terminology for Gastrointestinal Endoscopy, MST 3,0]. 2008. (in Russ.)

25. Lundell L. R., Dent J., Bennett J. R., et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classifi cation. Gut. 1999 Aug;- 45(2): 172–80. doi: 10.1136/gut.45.2.172.

26. Sharma P., Dent J., Armstrong D., et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology. 2006 Nov;131(5):1392–9. doi: 10.1053/j.gastro.2006.08.032.

27. Drapkina O. M., Maev I. V., Bakulin I. G., et al. Interim guidelines: "Diseases of the digestive organs in the context of a new coronavirus infection pandemic (COVID-19)". Pro fi la kti ches ka ya Medi tsina. 2020;23(3):2120–2152. (In Russ.) doi: 10.17116/profmed202023032120.

28. Forrest J. A., Finlayson N. D., Shearman D. J. Endoscopy in gastrointestinal bleeding. Lancet. 1974 Aug 17;2(7877):394–7. doi: 10.1016/s0140–6736(74)91770-x.

29. Shcherbakov P. L., Valiulin I. R., Ma li novskaya V. V., Pasechnik D. G., Agey ki na N. V., Shcher bakova M. Yu. Diagnosis and treatment of gastrointestinal involvement in the late post- COVID. Experimental and Clinical Gastroenterology. 2022;(11):234–241. (In Russ.) doi: 10.31146/1682–8658-ecg-207–11–234–241.

30. Jacob H, Lütcke A. Subakute sklerosierende Leukoencephalitis unter dem Initialbild einer akuten epidemischen Encephalitis (akute parkinsonistische Encephalitis) mit ausgeprägter Entwicklung von Maulbeerzellen und RussellKörperchen [Subacute sclerosing leukoencephalitis simulating acute epidemic encephalitis (acute encephalitic parkinsonism) with marked development of morular cells and Russell bodies]. J Neurol Sci. 1971 Feb;12(2):137–53. German. doi: 10.1016/0022–510x(71)90045–1.

31. Greenwood B. M., Whittle H. C. Cerebrospinalfl uid IgM in patients with sleeping- sickness. Lancet. 1973 Sep 8;2(7828):525–7. doi: 10.1016/s0140–6736(73)92348–9.

32. Russell W. An Address on a Characteristic Organism of Cancer. Br Med J. 1890 Dec 13;- 2(1563):1356–60. doi: 10.1136/bmj.2.1563.1356.

33. Ishido T, Mori N. Primary gastric plasmacytoma: a morphological and immunohistochemical study of fi ve cases. Am J Gastroenterol. 1992 Jul;87(7):875–8. PMID: 1615942.

34. Isobe Y, Chen S. T., Nakane P. K. et al: Studies on immunoglobulin translocation. Act histo Cito. 1977;10:161–177.

35. Jäck HM, Beck- Engeser G, Sloan B, Wong ML, Wabl M. A different sort of Mott cell. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11688–91. doi: 10.1073/pnas.89.24.11688.

36. Johansen A, Sikjär B. The diagnostic significance of Russell bodies in endoscopic gastric biopsies. Acta Pathol Microbiol Scand A. 1977 Mar;85A(2):245–50. doi: 10.1111/j.1699–0463.1977.tb00423.x.

37. Kanoh T, Uchino H, Kusaka M. Massive intramedullary globules in IgA monoclonal gammopathy associated with gastric carcinoma. Tohoku J Exp Med. 1977 Dec;123(4):343–9. doi: 10.1620/tjem.123.343.

38. Kopito RR, Sitia R. Aggresomes and Russell bodies. Symptoms of cellular indigestion? EMBO Rep. 2000 Sep;1(3):225–31. doi: 10.1093/embo-reports/kvd052.

39. Ohtsuki Y, Akagi T, Moriwaki S, Hatano M. Plasma cell granuloma of the stomach combined with gastric cancer. Acta Pathol Jpn. 1983 Nov;33(6):1251–7. doi: 10.1111/j.1440–1827.1983.tb02170.x.

40. Fujiyoshi Y, lnagaki H, Tateyama H, Murase T, Eimoto T. Mott cell tumor of the stomach with Helicobacter pylori infection. Pathol Int. 2001 Jan;51(1):43–6. doi: 10.1046/j.1440–1827.-2001.01154.x.

41. Tazawa K, Tsutsumi Y. Localized accumulation of Russell body-containing plasma cells in gastric mucosa with Helicobacter pylori infection: 'Russell body gastritis'. Pathol Int. 1998 Mar;48(3):242–4. doi: 10.1111/j.1440–1827.1998.tb03901.x.

42. Erbersdobler A, Petri S, Lock G. Russell body gastritis: an unusual, tumor-like lesion of the gastric mucosa. Arch Pathol Lab Med. 2004 Aug;128(8):915–7. doi: 10.5858/2004–128–915-RBGAUT.

43. Rubio CA, Nesi G. A simple method to demonstrate normal and metaplastic Paneth cells in tissue sections. In Vivo. 2003 Jan- Feb;17(1):67–71. PMID: 12655793.